Medical Sciences. In the article “CM101-mediated recovery of walking ability in adult mice paralyzed by spinal cord injury” by Artur W. Wamil, Barbara D. Wamil, and Carl G. Hellerqvist, which appeared in number 22, October 27, 1998, of Proc. Natl. Acad. Sci. USA (95, 13188–13193), the authors request that the following two corrections be noted. First, the following sentence on page 13188, “CM101 is an antipathoangiogenic polysaccaride (20) derived from group B streptococcus (GBS) (21) that inhibits angiogenesis and subsequent infiltration of inflammatory cells and thereby formation of granulation tissue, which produces scarring (M. Neeman, R. Abramowitch, B.D.W., and C.G.H., unpublished data),” should read “CM101 is an antipathoangiogenic polysaccharide (20) derived from group B streptococcus (GBS) that inhibits angiogenesis (21) and scarring (B.D.W. and C.G.H., unpublished data). Granulation tissue, which produces scarring, contains new capillaries and inflammatory cells [Rubin, E. & Farber, J. L., eds. (1994) Pathology (Lippincott, Philadelphia), 2nd Ed., p. 82].” Second, the reference to Dr. Michal Neeman on page 13192, “M. Neeman, personal communication,” should be deleted.